Bioventus Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	512.35	512.12	430.9	321.16	340.14	319.18
Revenue Growth (YoY)	0.04%	18.85%	34.17%	-5.58%	6.57%	-
Cost of Revenue	184.15	181.04	128.19	87.64	90.94	84.17
Gross Profit	328.19	331.08	302.71	233.52	249.21	235.01
Selling, General & Admin	303.88	332.13	254.25	193.08	198.48	191.67
Research & Development	13.45	23.85	19.04	11.2	11.06	8.1
Other Operating Expenses	131.26	163.02	19.1	13.33	29.99	29.87
Operating Expenses	448.59	519	292.39	217.61	239.52	229.64
Operating Income	-120.39	-187.92	10.32	15.91	9.69	5.37
Interest Expense / Income	40.68	12.02	1.11	9.75	21.58	19.17
Other Expense / Income	-4.92	3.13	-8.2	-11.44	-20.32	-3.26
Pretax Income	-156.15	-203.08	17.41	17.6	8.43	-10.54
Income Tax	0.09	-44.37	-1.97	1.19	1.58	1.66
Net Income	-156.23	-158.7	19.38	16.41	6.85	-12.21
Preferred Dividends	0	0	0	0	0	5.78
Net Income Common	-156.23	-158.7	19.38	16.41	6.85	-17.99
Net Income Growth	-	-	18.06%	139.54%	-	-
Shares Outstanding (Basic)	63	61	45	5	5	5
Shares Outstanding (Diluted)	63	61	45	5	5	5
Shares Change	2.05%	35.00%	828.01%	-	-	-
EPS (Basic)	-2.49	-2.59	-0.15	0.89	-0.13	-3.67
EPS (Diluted)	-2.49	-2.59	-0.15	0.89	-0.13	-3.67
Free Cash Flow	7.98	-23.58	9.47	55.22	38.37	42.63
Free Cash Flow Per Share	0.13	-0.38	0.21	11.27	7.83	8.70
Gross Margin	64.06%	64.65%	70.25%	72.71%	73.27%	73.63%
Operating Margin	-23.50%	-36.70%	2.39%	4.96%	2.85%	1.68%
Profit Margin	-30.49%	-30.99%	4.50%	5.11%	2.01%	-5.64%
Free Cash Flow Margin	1.56%	-4.60%	2.20%	17.19%	11.28%	13.35%
Effective Tax Rate	-	-	-11.29%	6.77%	18.70%	-
EBITDA	-58.1	-135.66	53.4	56	60.32	37.87
EBITDA Margin	-11.34%	-26.49%	12.39%	17.44%	17.73%	11.86%
Depreciation & Amortization	57.37	55.4	34.88	28.64	30.32	29.24
EBIT	-115.47	-191.06	18.52	27.35	30.01	8.63
EBIT Margin	-22.54%	-37.31%	4.30%	8.52%	8.82%	2.70%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).